



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Mulpleta

Page: 1 of 2

Effective Date: 1/3/2024

Last Review Date: 11/2023

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> New Jersey
	<input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Florida Kids	<input checked="" type="checkbox"/> Pennsylvania Kids
	<input type="checkbox"/> Texas	<input checked="" type="checkbox"/> Virginia	

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Mulpleta under the patient's prescription drug benefit.

### Description:

#### FDA-Approved Indication

Mulpleta is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

All other indications are considered experimental/investigational and not medically necessary.

### Applicable Drug List:

Mulpleta

### Policy/Guideline:

#### I. Exclusion

- Concomitant use of Mulpleta with other thrombopoietin receptor agonists (e.g., Doptelet, Promacta, Nplate) or with spleen tyrosine kinase inhibitors (e.g., Tavalisse)

#### Criteria for Initial Approval:

#### II. Authorization may be granted for thrombocytopenia in chronic liver disease when the following criteria are met:

- Documentation that member has an untransfused platelet count of less than 50 x 109/L taken within 14 days of the request
- Member is scheduled to undergo a procedure
- Medication is prescribed by or is in consultation with a hematologist, hepatologist or gastroenterologist

#### Criteria for Continuation of Therapy

#### III. Thrombocytopenia in chronic liver disease:

- All members (including new members) requesting authorization due to newly scheduled procedure must meet all initial authorization criteria
  - [Note: Continuation of therapy, defined as use beyond the initial approval for same procedure, is not approvable]

### Approval Duration and Quantity Restrictions:

**Initial and Renewal Approval:** 30 days



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Mulpleta

Page: 2 of 2

Effective Date: 1/3/2024

Last Review Date: 11/2023

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> New Jersey
	<input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Florida Kids	<input checked="" type="checkbox"/> Pennsylvania Kids
	<input type="checkbox"/> Texas	<input checked="" type="checkbox"/> Virginia	

**Quantity Level Limit:** 7 tablets per 14 days

**References:**

1. Mulpleta [package insert]. Florham Park, NJ: Shionogi Inc.; April 2020.